Intravenous Immunoglobulin and Prednisolone for RPL After ART.
Summary
Recurrent pregnancy loss (RPL) affects around 5 % of women in reproductive age. The underlying cause of RPL is most often unknown, probably multifactorial, and no treatment with documented effect on chance of live birth exists. In unexplained cases of RPL, primarily the immune system is hypothesized to play a pivotal, causative role, since autoantibodies and specific human leukocyte antigen (HLA) alleles as well as unbalanced distribution of leucocyte subsets, especially natural killer (NK) cells and T-helper (Th) cells, occurs more frequently in patients with unexplained RPL. For that reason, many treatment regimens used in autoimmune diseases have been tested on RPL patients, as for example prednisolone and intravenous immunoglobulin (IVIg). IVIg (Privigen) consist of a broad spectrum of structurally and functionally intact IgG antibodies. The mechanism of action is not fully elucidated, but certainly IVIg do help opsonise and neutralize foreign cells and pathogens. Prednisolone support this anti-inflammatory action by suppressing migration of polymorphonuclear leukocytes, and reducing the volume and activity of the immune system and the capillary permeability. A retrospective, observational pilot study suggested that a combination of prednisone and IVIg in first trimester improves the chance of a live birth in women with RPL after assisted reproductive technologies (ART) (Nyborg et al., 2014). A randomized controlled study is necessary for determining if this immunomodulatory treatment definitely is effective in patients with unexplained RPL after ART (defined as IVF or ICSI ad FER). Potentially, this study will be able to establish evidence for an effective treatment to women with unexplained RPL after ART, who otherwise have a poor prognosis.
Timeline
- Start
- 2021-01-28
- Primary completion
- 2024-04-18
- Completion
- 2024-04-18
Publications
- Norgaard-Pedersen C, Kesmodel US, Jorgensen MM, Christiansen O. Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a randomised, double-blind, placebo-controlled trial. BMJ Open. 2025 Nov 19;15(11):e106024. doi: 10.1136/bmjopen-2025-106024.
- Norgaard-Pedersen C, Nielsen K, Steffensen R, Eriksen L, Jorgensen MM, Kesmodel US, Christiansen OB. Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open. 2022 Sep 22;12(9):e064780. doi: 10.1136/bmjopen-2022-064780.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Human Intravenous Immunoglobulins | Protein / enzyme biologic | 25 g | Intravenous |
| Comparator | Human Intravenous Immunoglobulins | Protein / enzyme biologic | 30 g | Intravenous |
| Comparator | Human Intravenous Immunoglobulins | Protein / enzyme biologic | 35 g | Intravenous |
| Comparator | Prednisolone | Other / unclassified | 10 mg | Oral |
| Comparator | Albumin | Protein / enzyme biologic | 250 ml | Intravenous |
| Comparator | Albumin | Protein / enzyme biologic | 300 ml | Intravenous |
| Comparator | Albumin | Protein / enzyme biologic | 350 ml | Intravenous |